Sharon Richens, MD
Ophthalmology · St George, UTNPI 1497769368
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Rxsight Inc at 26.1% of the total. Reporting peaked in 2024 at $11,223 and has fallen 61.0% since, to $4,372 in 2025. Among ophthalmology clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 311 payments — averaging $83.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$7K
- Bausch & Lomb Americas Inc.$7K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$3K
- Biotissue Holdings Inc.$2K
- AbbVie$1K
- Glaukos Corporation$1K
- plus $5K from 27 others
Across 28 payments — averaging $354.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$10K
What the payments were for
- Consulting fees$11,22543%
- Speaking & faculty fees$260%
- Travel & lodging$2,0928%
- Food & beverage$12,02346%
- Education$3291%
- Gifts$1851%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 22 | $6,758 |
| Bausch & Lomb Americas Inc. | 45 | $6,739 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $3,032 |
| Biotissue Holdings Inc. | 17 | $1,637 |
| AbbVie(2 entities) | 44 | $1,253 |
| Glaukos Corporation | 27 | $1,248 |
| Alcon | 33 | $1,154 |
| Regeneron Healthcare Solutions, Inc. | 17 | $866 |
| Genentech USA, Inc. | 21 | $573 |
| Sight Sciences, Inc. | 10 | $345 |
| Ivantis, Inc | 2 | $299 |
| Novartis | 11 | $252 |
| Sun Pharmaceutical Industries Inc. | 7 | $247 |
| Amgen(2 entities) | 3 | $243 |
| Thea Pharma Inc. | 2 | $200 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $184 |
| Astellas Pharma US Inc | 7 | $151 |
| Tarsus Pharmaceuticals, Inc. | 6 | $122 |
| Oyster Point Pharma, Inc. | 4 | $102 |
| Dompe US, Inc. | 4 | $89 |
| LKC Technologies, Inc. | 2 | $66 |
| Carl Zeiss Meditec, Inc. | 1 | $58 |
| Apellis Pharmaceuticals, Inc. | 2 | $56 |
| Aerie Pharmaceuticals, Inc. | 2 | $40 |
| Genentech, Inc. | 1 | $27 |
| Coherus Oncology, Inc. | 1 | $22 |
| Nova Eye, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Eyepoint US, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Heidelberg Engineering, Inc. | 1 | $16 |
| Harrow Eye, LLC | 1 | $14 |
| Microline Surgical Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$6,088
- RXSIGHT INJECTOR CARTRIDGE$6,088
- RXSIGHT INJECTOR HANDPIECE$6,088
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$6,088
- LIGHT ADJUSTABLE LENS (LAL)$5,585
- VYZULTA$4,100
- TENEO$856
- VICTUS$827
- enVista Aspire IOL$715
- STELLARIS ELITE$715
- Hydrus Microstent$552
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$502
- Clareon$398
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$366
- EYLEA$247
- VABYSMO$243
- TEPEZZA$230
- DURYSTA$219
- ARGOS$141
- Photrexa Viscous and Photrexa$131
How this compares
$25,879 in reported general payments places this provider in the 95th percentile of 191 ophthalmology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 12 | $559,009 |
| RestasisCyclosporine | 62 | $61,480 |
| XiidraLifitegrast | 60 | $57,634 |
| VyzultaLatanoprostene Bunod | 122 | $55,570 |
| MieboPerfluorohexyloctane/Pf | 48 | $37,418 |
| TyrvayaVarenicline Tartrate | 46 | $35,100 |
| Cyclosporine | 62 | $15,527 |
| LumiganBimatoprost | 21 | $9,420 |
| Prednisolone Acetate | 180 | $8,402 |
| Bromfenac Sodium | 65 | $6,837 |
| Doxycycline Hyclate | 236 | $6,307 |
| Loteprednol Etabonate | 33 | $5,024 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $3,555 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 142 | $2,828 |
| MoxifloxacinMoxifloxacin Hcl | 137 | $2,719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $89 | $559,00912 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $6,739 | $150,623230 claims |
| AbbVieRestasis, Lumigan, Combigan | $1,253 | $74,45594 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $102 | $35,10046 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $3,032 | $5,02433 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 191 ophthalmology providers in Utah.
Other ophthalmology in St George
- David SladeSt George$8K
- Shawno MaySt George$4K
- William WagnerSt George$3K
- Iqbal AhmedSalt Lake City$895K
- Robert CionniSalt Lake City$161K
- Ron LordSt. George$61K
- Zachary ZavodniSalt Lake City$51K
- Majid MoshirfarSalt Lake City$44K
- Marc Steffen Schmitz-ValckenbergSalt Lake City$43K
- Rachel SimpsonSalt Lake City$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.